David G. Dolan is senior manager, Occupational, Environmental, and Quality Toxicology at Amgen Inc.

David G. Dolan

Submitted: July 25, 2016.
	Accepted: August 19, 2016.

A commonly used method in cleaning validation (CV) is 0.001 of the minimal daily dose (MinDD). This method lacks a consensus definition, as well as a source document where MinDD can be obtained. In November 2014, the European Medicines Agency (EMA) published a guidance document requiring the calculation of permitted daily exposure (PDE) limits. In this study, the authors investigated the relationship between the 0.001 MinDD and the PDE values for 140 drug substances as an attempt to identify high-risk groups of products for patient safety. This comparison can serve as a method for prioritization of APIs for development of PDEs.

	Chapters 3 and 5 of the European Union’s 

EudraLex Guidelines for Medicinal Products for Human and Veterinary Use

 require a toxicological evaluation to assess and control cross-contamination risks presented by the drug products manufactured in shared production facilities (1, 2). The European Medicines Agency (EMA) regulatory guideline on the setting of permitted daily exposure (PDE) values came into effect for all new human pharmaceutical products on June 1, 2015, and for all existing human pharmaceutical products on Dec. 1, 2015 (3). Presently, pharmaceutical companies are investing significant effort into providing the requested PDE values based on toxicological and pharmacological data for all their products manufactured in multipurpose facilities.

	In the past, several other methods were used in the pharmaceutical industry for determining an acceptable level of carryover with uncertain levels of patient health protection (4). One of the most frequently used methods was 0.001 of the minimum daily dose (MinDD). The use of 0.001 MinDD was proposed as the first of a set of three criteria, each of which had to be met, for determining acceptance limits for cleaning validation (5):

		No more than 0.001 of the minDD of any product will appear in the maximum daily dose of another product.

		No more than 10 ppm of a product will appear in another product.

		No quantity of residue will be visible on the equipment after cleaning procedures are performed.

	The dose criterion makes no distinction between solid or liquid forms, or between the different routes of administration (topical, parenteral, inhalation). The core issue with the first criterion, however, is the absence of a clear and health protective definition of the term MinDD, in particular, one that resolves the operational issues in deriving the MinDD. The terminology and definitions were recently discussed (6). In the absence of an operational definition from a regulatory or consensus organization, the answer to what constitutes the MinDD has been subjectively established by each pharmaceutical company based on explicit or implicit decisions and judgments on these key issues:

		Is the minimum daily dose the smallest therapeutic daily dose administered to healthy adults, or should it encompass all potentially sensitive subpopulations and requisite dosing reductions (e.g., patients with underlying disease [such as renal or hepatic impairment], patients taking concomitant medications with potential drug interactions, pediatric patients, or pregnant or nursing women)?

		How do you deal with complex posology (dose, frequency, and method/route of administration)?					

				For drugs that are administered chronically on an intermittent basis (e.g., once a week or once a month), is it appropriate to divide the bolus dose by the number of days between doses (e.g., 7 or 30) in the calculation of the MinDD?

				For medications that are administered only once or only a small number of times in a lifetime (e.g., anesthetics or medications for reversal of neuromuscular blockade after surgery) but could potentially cross-contaminate drugs that are administered daily, can this single dose value be used, or would it be appropriate to include a factor for lifetime daily exposure in the calculation of the MinDD?

				For medications with differences in routes of administration between the initial and subsequent drug product, should differences be considered in relative bioavailability in the calculation of the MinDD, as for instance, the carryover of a parenteral drug with low oral bioavailability into a subsequent oral drug?

		How do you calculate the MinDD for a drug that is not approved or is contraindicated for a subpopulation that could potentially receive it through cross-contamination? As an example, drugs previously classified as FDA Category D or X should not be administered to pregnant women. Does it make sense to use the MinDD of nonpregnant females or healthy males (e.g., angiotensin-converting enzyme inhibitors) as the basis of MinDD in such carryover calculations?

		What confidence is there in 0.001 MinDD for a drug that may cause serious adverse effects from a single or small number of doses (e.g., anaphylaxis from a residual beta-lactam antibiotic, embryo-fetal toxicity from an antineoplastic such as thalidomide)?

	In practice, varying responses to these questions has resulted in different cleaning limits with the MinDD criterion. These questions also highlight the ambiguity of the former methodology, and how arbitrary decisions or judgments could result in profound differences in carryover limits.

	Others have recently proposed methods to establish expedited PDE values based on occupational exposure levels (OELs) and occupational exposure bands (OEBs) (7). The availability of OELs and OEBs may be helpful to prioritize these substances for PDE-setting, but are of limited validity as surrogates for PDEs given that OELs and OEBs are derived to protect healthy adult workers and focus principally on the inhalation route of exposure. Consequently, they are subject to some of the same issues as MinDD described (e.g., differences in therapeutic routes of administration and protection of sensitive sub-populations). In the present article, the authors investigated the mechanism of action (MOA) or therapeutic area of 140 drug substances (DS) and compared their PDE values with the 0.001 MinDD in effort to help identify the critical drug product types that are of highest priority with regard to expert toxicological evaluation and PDE determination. This prioritization tool can be helpful for those companies that have large portfolios of legacy APIs that need to be assessed by expert toxicologists as well as the auditors that are looking for a tool to identify patient safety critical substances.

	The study evaluated 140 drug substances manufactured by Novartis. PDE values were calculated following the EMA guideline and recently published criteria (8-11). PDEs were compared to the MinDD used in therapy divided by a factor of 1000 (0.001 MinDD). The quotient of these two values was termed R. The minimum therapeutic dose for these calculations was based on the lowest known therapeutic or the starting dose identified in the published literature. To avoid the confounding effects from adjustments necessary to account for different routes of administration (e.g., topical, parenteral, inhalation), the same route of administration was assumed for a subsequent drug in these comparisons (e.g., PDE oral in μg/day with 0.001 MinDD in μg/day used in oral treatment). For the purposes of simplification, drugs that do not have a daily dosing regimen were excluded from this evaluation.

	The comparison of the PDE value by route of administration with the respective 0.001 MinDD is shown in 

. The ratio R=PDE/0.001 MinDD for the 140 drug substances investigated was plotted in decreasing order. Red bars indicate therapeutic substances where R < 1.

	There were 9% (n=12) out of the 140 drugs evaluated in the group with R < 1, and 11% (n=16) of the group with 1 ≤ R <10; 26% (n=37) of the drugs evaluated had 10 ≤ R <50, and 53% (n=75) of substances had R≥50. Depending on a company’s drug portfolio, these percentages would be different. For example, a company that has a large oncology portfolio might have a higher percentage of substances with R <10. 

 presents all of the drug substances with R<10, which includes all of the antineoplastic medications. The drugs that really stand out in this comparison of PDEs and MinDD derived carryover limits are the antineoplastic agents and the organ transplantation anti-rejection drugs.

	This observation makes sense as most older antineoplastic agents (e.g., alkylating agents, antimetabolites, antibiotics, and topoisomerase inhibitors) interact directly with DNA or its precursors, causing indiscriminant damage to normal and malignant cells (12). These agents, with several other mode of action (MOA), are known to be able to affect fertility or embryo-fetal development (EFD). Additionally, many of them, in particular, the first- and second-generation antineoplastics, are genotoxic. Generally, antineoplastic drugs are administered to cancer patients at high doses, often at the maximum tolerated doses for patients, while effects on EFD may occur at much lower doses. Therefore, PDEs are lower than 0.001 MinDD for most anticancer substances, and use of 0.001 MinDD as a carryover limit could potentially pose a risk to patients.

Doxorubicin is an example of an antineoplastic that has a PDE 10-fold lower than 0.001 MinDD. Doxorubicin causes nucleotide base intercalation and has apparently prolonged tissue binding activities that affect its excretion. Independent of the primary mechanism of cell damage, the cellular response is frequently apoptosis. Doxorubicin was embryotoxic and teratogenic in preclinical studies. It is positive in several genotoxicity studies and is classified by the International Agency for Research on Cancer (IARC) as Group 2A (probably carcinogenic to humans) based on sufficient data from animals (13). Its lowest therapeutic dose is 20 mg/m

 weekly and was, therefore, excluded from the evaluation in 

. Doxorubicin is not suitable for oral administration as less than 5% of the drug is absorbed. Its terminal half-life is approximately 20-48 hours. Impairment of liver function results in slower excretion and, consequently, increased retention and accumulation in plasma and tissues (14). This example shows a number of factors that would lower the PDE value below the 0.001 MinDD, such as adverse effects in reproduction/development, genotoxicity, carcinogenicity, nondaily administration, potential for accumulation, and sensitive subpopulation of patients (e.g., those with liver damage or pregnant women). Clearly, there could be a significant risk to patients from carryover if the MinDD, which is based on once per week dosing, were used as the basis for the calculation.

	Another group of substances that have R<10 are sex hormone modulators indicated as antineoplastics. Examples in this group are estrogen receptor antagonists and estrogen receptor modulators, which can cause adverse effects on reproduction and EFD. In this group, estrogen receptor agonists, in addition to the EFD effects, were found to also have carcinogenic potential. Aromatase and androgen receptor inhibitors, as well as antiandrogens, are also consistently found in the group where R<10. For example, tamoxifen citrate is a selective estrogen receptor modulator (SERM). Tamoxifen and several of its metabolites are thought to act as estrogen antagonists by competitively binding to estrogen receptors on tumor and other tissue targets, producing a nuclear complex that decreases DNA synthesis. This mechanism appears to cause cells to accumulate in G0 and G1 phases and may induce apoptosis independent of estrogen receptor expression. It is also recognized that tamoxifen acts as an estrogen agonist on endometrium, bone, and lipids. Primary uses of tamoxifen are brain tumors, breast cancer, melanoma, and soft tissue sarcoma. Other uses are carcinoid tumor, endometrial cancer, and pancreatic cancer. Reproductive toxicity and non-genotoxic carcinogenicity have been reported for other SERMs such as raloxifene hydrochloride and lasofoxifene tartrate. Raloxifene and lasofoxifene have been shown to be teratogenic whereas tamoxifen may be potentially teratogenic (15).

	In contrast to the mentioned hormone or hormone modulating substances, there are other agents from the same group that pose a lower risk to patients. Progestogens, progestins, and corticosteroids generally have PDE values greater than 0.001 MinDD. Equally low priority drugs are thyroid hormones and their modulators or peptide hormones such as vasopressin, oxytocin, and prolactin even though their absolute PDE values may be low.

I, there are several immunosuppressive or immunomodulating substances indicated for use in organ transplantation, such as cyclosporine A, mycophenolate mofetil, and mycophenolic acid. These substances may cause adverse effects in pregnancy and are dosed in relatively high doses in patients undergoing organ transplantation. Cyclosporine A is a calcineurin inhibitor, and mycophenolate mofetil and mycophenolic acid are purine synthesis inhibitors. An additional adjustment factor is assigned to these medicines because of concern for their potential to cause adverse effects on reproduction or development. Conversely, mammalian target of rapamycin (mTOR) inhibitors such as tacrolimus and everolimus have R > 100 because adverse effects on reproduction-development are not driving the PDE values. If the adverse effect profile of these substances would be entirely due to the pharmacological action of the substance, the likelihood that the PDE would be lower than 0.001 MinDD is low. However, as these adverse effects are pharmacologically-mediated, their R-ratios are higher. The PDE is established to prevent any adverse effects, whether pharmacologically- or toxicologically-mediated.

	Antiviral substances may potentially have genotoxic, developmental, or reproductive effects. These effects lower the PDE values because an additional adjustment factor for severity of effect is applied. One example is ribavirin, which has a PDE value lower than 0.001 MinDD due to adverse effects on fertility and EFD and a long elimination half-life of more than 150 hours, and therefore, a potential for accumulation with the assumption of repeated daily exposure required for PDE calculations.

	The authors evaluated the 14 antibiotics in their company’s portfolio, none of which were beta-lactams. Some of these antibiotics have very high MinDD values, including neomycin, with a MinDD of 33 g/day. The R was typically around 10 because these antibiotics may be skin or respiratory sensitizers, which typically result in low PDE values.

	There were four antibiotics out of 14 that had R<10: chloramphenicol, two aminoglycosides (gentamycin, and neomycin), and tigecycline, a tetracycline antibiotic. The aminoglycosides amikacin, gentamycin, kanamycin, neomycin, netilmycin, paromomycin, spectinomycin, streptomycin, and tobramycin inhibit protein synthesis in gram-negative bacteria and have bactericidal activity. Aminoglycosides rapidly cross the placenta. Aminoglycosides cause nephrotoxicity and ototoxicity. Congenital hearing loss has been documented in association with prenatal exposure to streptomycin and kanamycin, but not with the use of gentamycin and tobramycin. This distinction between the substances within the same class of antibiotics shows the importance of the toxicological and pharmacological evaluation in discriminating patient safety issues even with the same class of drug. In addition, aminoglycosides pose a potential risk for skin sensitization, which has been observed in patients who have applied the drug topically. Neomycin has an oral MinDD of 3000 mg/day and equally high oral PDE values. Due to its low oral bioavailability (less than 10%), the PDE intravenous is lower than oral; however, high maximal safe carry-over limits are expected to exceed other quality criteria in cleaning, such as visually clean.

	A number of antibiotics have effects other than just those on bacterial growth. For example, trimethoprim is a folate antimetabolite and thus has the potential for EFD effects. Chloramphenicol was also found to have R<10. Chloramphenicol is relatively toxic and can cause severe agranulocytosis. It readily crosses the placenta and can reach therapeutic concentrations in the fetus. It is genotoxic and has been classified by IARC in Group 2A, as probably carcinogenic to humans (13). Tetracyclines cross the placenta, and they bind strongly to calcium ions. From the sixteenth week of pregnancy, tetracyclines are strongly bound in this way in developing tooth and bone structures, causing brown permanent discoloration of deciduous teeth and inhibition of bone growth. They can cause liver toxicity in the mother and are contraindicated in pregnancy and in children younger than eight years of age.

	Fluoroquinolone antibiotics have a narrow range of doses between the minimal and maximal daily doses. For those substances, a larger factor is applied to the therapeutic dose to get from a lowest observed adverse effect level (LOAEL) to no observed adverse effect level (NOAEL). In addition, as they may cause hypersensitivity reactions, an additional factor for severity of effect is incorporated into the PDE calculation.

	Macrolide antibiotics are not considered high priority APIs, despite issues with erythromycin, which is considered a skin and respiratory sensitizer. Erythromycin is considered a safe and effective antibiotic during pregnancy. Other macrolides are also generally safe to be used in pregnancy.

	Polypeptide antibiotics are considered low in priority as they have not shown any effects on embryo-fetal development. Vancomycin has a high MinDD of 500 mg/day orally (indicated for the treatment of staphylococci enterocolitis and pseudomembranous colitis caused by Clostridium difficile in the gastrointestinal tract) and 1000 mg/day with intravenous administration (indicated for the treatment of systemic infections caused by gram-positive bacteria including staphylococci and streptococci). It is poorly absorbed from the gastrointestinal tract. The carryover values calculated for this substance are expected to be above the visually clean criteria. Teicoplanine has a very long elimination half-life and, therefore, the potential for accumulation, which is accounted for in the PDE calculation.

	For an innovator company, the PDE calculation for a drug is based on a review of the totality of clinical and nonclinical data to identify the NOAELs and LOAELs from the most relevant regulatory documents available, such as the investigator’s brochure or the core data sheet, supplemented by review of the literature for compounds with the same target. After adjustment, the lowest of these values termed the point of departure (POD), which is a dose that should not cause a significant pharmacological or toxicological effect, serves as the basis of the PDE calculation. For example, the lowest oral therapeutic dose of irbesartan is 75 mg/day, but its lowest pharmacologically active dose is 10 mg/day. There is a seven-fold difference between these two values.

	In the absence of the minimal pharmacologically active dose, there may be a different dose used in the initial therapy than in maintenance. For carbamazepine, the initial dose is 100 to 200 mg once or twice daily and the maintenance dose is 400 mg two to three times daily. The 12-fold difference between the lowest starting dose (100 mg/day) and highest maintenance dose (3x 400 mg/day = 1200 mg/day) simply reemphasizes one aspect of the problematic nature of the MinDD in the calculation of safe carryover limits.

	Also, when tabulating the MinDD values, it is important to include the route of administration. Toxicological documentation usually provides oral, parenteral (e.g., intravenous or intramuscular), and inhalation PDE values for each substance. These values may be significantly different because of differences in bioavailability. For example, zoledronic acid, ibandronate, and pamidronate are bisphosphonates indicated for the treatment and prevention of bone diseases, including hypercalcemia of malignancy, osteolytic bone metastases from solid tumors and osteolytic lesions of multiple myeloma, postmenopausal osteoporosis, and Paget’s disease. They have a low oral bioavailability of <10%. Therefore, selecting an intravenous MinDD when the next substance produced in the same equipment is dosed orally would give a conservative approach. Another example is some of the antibiotics. Neomycin was previously mentioned as an example of a drug that is indicated for different treatments with oral and intravenous administration. Selecting the appropriate route for MinDD is, therefore, crucial. The PDE value considers the pharmacokinetic and pharmacodynamics effects appropriately in the calculation of PDEs for various routes of administration.

	When substances are dosed with non-daily dosing regimen, the MinDD may not be an appropriate value without extrapolating to a daily dose. For example, the recommended dose of pamidronate for the treatment of predominantly lytic bone metastases and multiple myeloma is 90 mg administered as a single infusion once every four weeks. Extrapolation from 90 mg/28 days to daily dose is 3.2 mg/day pamidronate disodium. When the PDE is calculated, the extrapolated daily dose is taken as a point of departure (POD), given that the definition of the PDE is a safe dose for daily administration. It is doubtful whether the dosing regime has been routinely incorporated into the MinDD values used as a basis for safe carryover calculations. The non-daily dosing can be considered in the product-specific PDE values. The issues of establishing a product-specific PDE, when the following drug product is known, and methods to derive these values are discussed elsewhere (16).

	Lastly, the substances that are either dosed only for short treatment duration or substances that are dosed with non-daily treatment regime may have long elimination half-lives and a potential for accumulation. For example, netupitant, a neurokinine-1 (NK-1) receptor antagonist indicated as an antiemetic, has a mean elimination half-life of 86.3 hours. Accumulation of netupitant has been observed in a repeated-dose study with a once-per-day dosing frequency. Therefore, in the calculation of the PDE for netupitant, a factor of five was applied for accumulation.

	Data are presented comparing safe carryover limits derived from PDEs and 0.001 MinDD for 140 different APIs. Grouping these medications by therapeutic use or MOA differentiates between medications that would potentially pose a risk for patients. Antineoplastics have consistently had 0.001 MinDD values less conservative than PDE values. In addition, the adverse effect profile (EFD effects, genotoxicity, carcinogenicity, and other off-target effects), potential for accumulation, and non-daily dosing regimen of a drug will drive the PDE value potentially below the 0.001 MinDD. The MinDD in this study is useful in demonstrating how a pharmaceutical company could prioritize its drug portfolio to identify those requiring comprehensive assessments as a first priority. The results further show that there are limitations of the MinDD criterion and support the use of the PDE limit for cleaning validation.

	The authors would like to thank Michel Crevoisier for his valuable input.

EudraLex: The Rules Governing Medicinal Products in the European Union, Part I--Basic Requirements for Medicinal Products

. Volume 4. EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use. Chapter 3: Premises and Equipment (Brussels, August 2014).
	2. European Commission, 

. Volume 4. EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use. Chapter 5: Production (Brussels, August 2014).
	3. EMA, 

Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities

 (EMA/CHMP/ CVMP/ SWP/169430/2012), (London, Nov. 2014).
	4. E. Lovsin Barle et al., 

 32, 18-23. (2014).
	5. G.L. Fourman and M.V. Mullen, 

., 17 (4) 54-60 (1993).
	6. M. Olson et al., 

. 79 Suppl 1:S19-27 (2016).
	7. A. Teasdale et al., 

., 40 (1) 58-62 (2016).
	8. J.P. Bercu et al

. 79 Suppl 1:S48-56 (2016).
	9. J. Gould et al., 

. 79 Suppl 1:S79-93 (2016).
	10. J.F. Reichard et al., 

. 79 Suppl 1:S67-78 (2016).
	11. R.G. Sussman et al

. 79 Suppl 1:S57-66 (2016).
	12. B.A. Chabner, “Chapter 60: General Principles of Cancer Chemotherapy” in 13. 

Goodman and Gilman’s The Pharmacological Basis of Therapeutics

, L. L. Brunton, B. A. Chabner, and B. C. Knollmann, Eds. (McGraw-Hill Professional, New York, 12th ed., 2011), pp. 1667-1675. 
	13. IARC, Agents Classified by the IARC Monographs, Volumes 1-112 (Alphabetical Order), April 7, 2015. Lyon, France: World Health Organization, International Agency for Research on Cancer (2015).
	14. Pfizer Canada Inc., Product Monograph: Adriamycin PFS* doxorubicin hydrochloride injection, 2 mg/mL (revised August 22, 2014).
	15. J.C. Berger and C.L. Clericuzio. 

, 146A (16) 2141-2144 (2008).
	16. J.P. Bercu, R. Sharnez, and D.G. Dolan. 

	Ester Lovsin Barle, PhD*, is head of Health Hazard Assessment at Global Health Safety and Environment and Business Continuity Management, Novartis AG, 

; Camille (Bossard) Jandard, Pharm.D, MSc, is toxicology project leader and occupational toxicologist at Biologie Servier, 905 route de Saran, 45520 GIDY, France, 

; Markus Schwind, PhD, is HSE manager at Sanofi-Aventis Deutschland GmbH, HSE Germany, Industriepark Hoechst, Bldg. H831, Room A.04.72.2, D-65926 Frankfurt am Main, 

; Gregor Tuschl, PhD is principal scientist, Early Non-Clinical Safety, Merck KgaA, Frankfurter Str. 250, U009/101, 64293 Darmstadt, Germany, 

; Claudia Sehner, PhD, is principal scientist, Nonclinical Drug Safety, Boehringer Ingelheim Pharma GmbH & Co. KG, 

; and David G. Dolan, PhD, is a senior manager, Occupational, Environmental & Quality Toxicology, Product Stewardship, Environment, Health, Safety and Sustainability (EHSS), Amgen Inc., 

	*To whom all correspondence should be addressed.

	When referring to this article, please cite it as E. Barle et al., “Comparison of Permitted Daily Exposure with 0.001 Minimal Daily Dose for Cleaning Validation," 

Articles

In this study, the authors investigated the relationship between the 0.001 MinDD and the PDE values for 140 drug substances as an attempt to identify high-risk groups of products for patient safety. This comparison can serve as a method for prioritization of APIs for development of PDEs.


Comparison of Permitted Daily Exposure with 0.001 Minimal Daily Dose for Cleaning Validation

In a previous article, the authors discussed the lack of scientific justification for the 10-parts-per-million (PPM) limit commonly used in cleaning validation and the lack of any regulatory requirement for it (1). This article discusses how the 10ppm limit, along with the 0.001 dose limit, are not truly risk-based approaches and are also unsound from an operational standpoint as they have caused unnecessary difficulties for many companies. A statistical process-based approach to demonstrate that acceptable cleaning has been achieved compared to a health-based limit is proposed.
	
	The use of a default limit value expressed as a concentration (ppm) has its origins in food safety concerns related to pesticide residues (2). The value of 10 ppm comes from an article written by Gary Fourman and Dr. Michael Mullen more than 20 years ago (3), which suggested a combination of the following for setting acceptance limits for cleaning:
	 

		No more than 0.001 dose of any product will appear in the maximum daily dose of another product

		No more than 10 ppm of a product will appear in another product

	
	Since that time, many pharmaceutical companies have adopted some or all of the criteria suggested in this article, including the 10-ppm value (4). Due to difficulties and inconsistencies in the application of these approaches to the wide variety of pharmaceutical dosage forms, some modifications to these limits were suggested such as using 0.01 or 0.1 (5). Some companies have had issues meeting these limits, in particular the 10 ppm, and have moved to higher values, and some have even published their justifications (6). Consequently, no single, consistent approach exists for setting limits for cleaning validation (2).

	In 2010, the International Society of Pharmaceutical Engineering (ISPE) published its 

Risk-Based Manufacturing of Pharmaceutical Products (RiskMaPP) Baseline Guide

 (7) that introduced the acceptable daily exposure (ADE) as the appropriate value for assessing pharmaceutical manufacturing risks, including for cleaning validation, as it is a value based on all the available pre-clinical and clinical data for a compound. The European Medicine Agency (EMA) uses the term permitted daily exposure (PDE), which it has declared to be “effectively synonymous” with ADE and defines it as “a substance-specific dose that is unlikely to cause an adverse effect if an individual is exposed at or below this dose every day for a lifetime” (8).

	Although the PDE is very conservative and has a superior scientific basis compared with previous approaches, there has been some objection and resistance to the use and implementation of PDE (9) but nothing substantive has ever been published in a peer-reviewed journal. In 2014, EMA issued a guideline that required all companies to develop PDEs by June 2015 for any medicinal product newly introduced into shared manufacturing facilities. It also required that PDEs be used to identify risks by December 2015 for medicinal products already produced in a shared manufacturing facility (8).

	While the guideline was being developed, some biopharmaceutical companies lobbied against it, asserting that their products are denatured or degraded by cleaning and should therefore be exempt from the requirement to establish ADEs for such drug products. EMA subsequently provided language in the final version of the guideline permitting these companies to use “alternative approaches” if they can be “scientifically justified.”

	It has been demonstrated, however, that within the risk-based approach of International Council for Harmonization Q9 (10), the risk associated with any residual biologic (i.e., based on its ADE) still must be addressed (11). Also, some companies have been trying to justify retaining the use of 10ppm and 0.001 dose limits because in many cases these old approaches result in lower limits than the ones based on ADEs. Their rationale is that the most stringent limit of the three limit-setting methods should be imposed.

	The following discussion addresses why retaining either the 10ppm or the 0.001 dose limits is unwarranted. First, neither of them are “health based” and, therefore,  not “risk-based.” Second, they have caused many operational issues, and third, and more importantly, they actually interfere with an appropriate risk assessment, which should now be necessary in accordance with ICH Q9.
	 

	0.001 dose limits are not truly health-based

	The issue of the 0.001 dose limits not being health-based has been addressed in a previous article (2) and will be revisited briefly here.

 shows how three compounds with widely varying severity of hazards (low to high) will have cleaning limits set using the 0.001 lowest clinical dose approach that are inconsistent with a health-based assessment. The fundamental problem with basing a cleaning limit on the therapeutic dose is that the choice of medication and dose is tailored to an implicit risk-benefit medical decision for individual patients who are suffering from a particular disease or condition, which may be contraindicated in other patient populations. For example, a pregnant woman who takes a Cetirizine hydrochloride tablet should not be exposed to unsafe levels of teratogenic drugs such as Ribavirin or oncology drugs such as Capecitabine. So logically, how could the cleaning limit for Cetirizine hydrochloride be set so much lower than that for a teratogen or anti-cancer drug?


	
	This simple comparison should be sufficient evidence that the use of 0.001 of the lowest therapeutic dose ignores the underlying scientific data for a drug. If the first effect of a substance (also known as lead effect) is identical with the desired therapeutic effect, then there is a direct relationship between the therapeutic dose and the no-observed-effect level (NOEL) of this substance. In many cases though it is sufficient to lower the therapeutic dose by a factor much less than 1000 to reach this NOEL; for a few drugs, however, a factor higher than 1000 may be necessary. If the lead effect of the substance is qualitatively different from the desired therapeutic effect (e.g., teratogenicity or genotoxicity), then this effect may have a different dose-response curve from the dose-response curve of the desired effect in the target patient. In cases where there is no correlation at all between the NOEL for the lead effect and that for the therapeutic dose, the ADE cannot be a simple fraction of the therapeutic dose.

	The principles behind applying risk in pharmaceutical manufacturing were introduced in the ICH Q9 (formally adopted by FDA and the Ministry of Health, Labour and Welfare (MHLW) in 2006) and its applicability to cleaning (including acceptance limits) mentioned in its Annex II.4 and to validation mentioned in Annex II.6. In accordance with ICH Q9, risk can be defined as 


	
	Likewise, risk can be defined as a function of the probability of adverse health effects arising from exposure to a hazard. The types and probabilities of effects from exposure to a drug are API-specific and dose-dependent. Consequently, for cleaning if the identified hazard is an API then the above equation for risk can be expressed as 

 provides the measure of the severity of the hazard that the API presents in long-term exposure. It should be noted that this concept can be applied to any agent, not just APIs.

	The ADE for an API (or any compound) provides a value that can be substituted for the “severity of harm” in Equation 1 (as shown in 

); but what value should be substituted for “probability of exposure”?
	 

 shows the “probability of exposure” to API residues can be determined by comparing the data collected during cleaning to the limits calculated from the ADE of the API. The distance between the data and the ADE-based limit provides the margin of safety and indicates the probability of patient exposure to the API residues resulting from ineffective cleaning. If this margin of safety could be measured, then this value could be used for the “probability of exposure” parameter in 

	A simple statistical method has already been presented for quantifying the “margin of safety” and that is the process capability index (Cpk) or more precisely Cpu (12, 13). The Cpu measures the capability of a process only for an upper specification limit (USL). It is a simple, straightforward comparison of the spread of the data (its variability) to the distance between the mean of the data and the upper specification limit (


	
	This equation can be satisfied using cleaning data such as shown in 

	Readily available software provides powerful statistical and graphical abilities that can calculate the Cpu and quickly help visualize the relationship of data to limits. 

 shows a comparison of two cleaning processes against ADE-based limits using Minitab 17 (14).

, residue data for a cleaning process are distributed well below the ADE-based limit, thereby providing a very wide “margin of safety,” and hence a very low probability of patient exposure. On the right, however, residue data for a cleaning process are distributed relatively close to the ADE-based limit, thereby not providing an adequate “margin of safety.” Consequently, this scenario presents a high probability of patient exposure. It should be noted that although no individual data point failed the limit on the right (they would pass in a traditional cleaning validation), the statistical evaluation demonstrates that failures are likely (PPM > USL = 13,532) and the cleaning process has a risk of failures (i.e., exceeding the ADE-based limit).

	It can be seen that the Cpu can be easily used as a measure for the “probability of exposure” parameter in the cleaning validation risk evaluation.

 shows an actual evaluation of a very low hazard product using total organic carbon (TOC) analysis. Using the ADE, the calculated swab limit was 3179ppm (USL value) in the analytical sample. Because the cleaning procedure was effective, the TOC swab results were far below this limit, resulting in a Cpu value of 6120 with a lower 99% confidence limit for the Cpu of 3084. To put this result into perspective, in a Six Sigma organization, the goal for a process capability is only 2. Clearly, this analysis shows a very low-risk cleaning situation.

	How 0.001 dose limits interfere with the evaluation of risk

	The implementation of the ADE as the starting point in limit calculations for cleaning validation has required revisiting older calculations that use 0.001 dose and 10 ppm. This has revealed situations where the previous limits were not low enough and potentially posed a risk to patients, and situations where the previous limits were lower (often much lower) than those calculated using the ADE.

 shows a comparison of the ADE values vs. 0.001 of the lowest clinical dose for 304 pharmaceutical products (data were provided by several pharmaceutical companies). The data were plotted as a ratio of the ADE to the 0.001 dose, which makes 1.00 on the Y axis the point at which the ADE equals the 0.001 dose (Note: the ratios had to be plotted on a logarithmic scale in order to get all the data on one graph because the values of the ratios varied widely).

	These ratios show that, in more than 15% of the cases, the ADE was lower than the 0.001 dose including two instances in which the ADE was 100 times lower indicating a potential issue for patient exposure. However, these ratios also show that in 85% of the cases, the 0.001 of the lowest clinical dose was lower than the ADE. In fact, of these cases, 47% were 10 times lower, 12% were 100 times lower, and there were six instances that were 1000-8000 times lower than the ADE. This demonstrates that, for the vast majority of drugs, the 0.001 dose limit has been overly conservative.

	While at first it may be startling to realize that most cleaning acceptance limits based on the use of 0.001 dose have been grossly overstated, the most important thing to realize about the increase in cleaning acceptance limits for most APIs as a result of implementation of health-based ADEs is its impact on the ability to evaluate the true risk. 

 shows how the true margin of safety can now be measured using the ADE-based cleaning acceptance limit. Where cleaning data were close to failing using the 0.001 dose-based limits and had a poor Cpu, moving to the ADE-based limits shows that there is a wide margin of safety and an excellent Cpu.

 is a comparison of the ADE/0.001 dose data of one of the products from 

. A hypothetical set of TOC swab data with a mean of 75 parts per billion (ppb) and a standard deviation of 7.5 ppb was evaluated against analytical swab limits calculated using both the ADE and the 0.001 dose limits for that product. The calculation of both analytical swab limits assumed a maximum daily dose of 1000 mg, a batch size of 500kg, and a total surface area of 100,000 in

 for the next product. For sampling, a swab area of 100 in

, a dilution volume of 10 mL, and a recovery factor of 100% were assumed. This resulted in an ADE-based analytical swab limit of 250,000 ppb and a 0.001 dose-based analytical swab limit of only 100 ppb.

, there is a wide margin of safety with a Cpu of 9224 even for the 99% lower confidence level. Because they are calculated from the mean and standard deviation, Cpus can have confidence intervals calculated just as any mean can). Using the 0.001 dose-based limit, there is no margin of safety and a Cpu of only 0.84 for the 99% lower confidence level. The true margin of safety cannot be measured using the 0.001 low-clinical dose-based limit methodology. Applying the 0.001 low-clinical dose based limit, the process capability is artificially low across most of the compounds and could likely lead to false conclusions of cleaning failures for low risk products.

	How 10-ppm limits interfere with the evaluation of risk

	Back in 1993, Fourman and Mullen had recognized that limits calculated based on dose increased as the potency decreased and resulted in higher and higher limits for low potency (i.e., high therapeutic dosage) drugs (3). To account for this effect, they suggested that a 10-ppm limit be imposed when the 0.001 low-clinical dose-based limit went too high and the maximum allowable carryover (MAC) into the next batch would exceed 10 ppm. The only justification these authors provided was that maximum allowable ppm limits were used in the food industry. There was no explanation as to why a maximum value of 10 ppm was selected. In the graphical representation in 

, the implications of imposing the arbitrary lower limit of 10 ppm criterion after applying the 0.001 dose-based limit are seen. The end result is that, after a certain point, all lower potency drugs have the same cleaning acceptance limit, regardless of how low their potency or how low their risk levels are.

, the true margin of safety cannot be measured when imposing the 10-ppm limit as shown in 

. The 10-ppm limit simply cuts off, or truncates, the ability to measure the margin of safety, making a relatively low-risk compound look like a high-risk compound, because the 10-ppm limit is only imposed when the 0.001 dose limit is higher than the 10-ppm limit. 

 illustrates a hypothetical example of a low potency drug where the ADE is higher than the 0.001 dose-based limit, which in turn is higher than the 10-ppm criterion (data not to scale).

	The recent implementation of a regulatory requirement mandating the use of health-based cleaning limits for shared medicinal manufacturing facilities has resulted in a significant increase in the level of cleaning limits for most drugs. It should be understood that the previous use of 0.001 low-clinical dose limit, in the case of most APIs, has been excessively conservative, which has caused significant needless complications with manufacturing operations, especially for low-hazard products. Many companies have gone from using disposable items such as scoops and other utensils, and modifying manufacturing schedules, to dedicating parts, pieces of equipment, or even entire manufacturing lines to deal with these artificially low limits, all the while knowing that their products were low risk. While there have been calls to return to the 10-ppm and 0.001 dose limits as they are more stringent, this reversion would simply have the industry using limits that do not consider all the pre-clinical and clinical data available for each API. And worse, it would perpetuate the many unjustified operational issues for low-hazard products. If the argument for stringency was truly valid, the case should be made to move to a 0.00001 low-clinical dose limit to also cover those 15% of the compounds where the ADE concept has revealed that the 0.001 low-clinical dose limit has been insufficiently protective. Thus, reverting to the 0.001 low-clinical dose limit would be against the science- and health-based evaluation process EMA has sought to institute for cleaning validation. Moreover, such a move would lead to many products being falsely judged as failing cleaning validation, and perhaps ultimately requiring their manufacture in dedicated facilities. The proposal to keep cleaning limits as low as possible is not a valid argument if the real goal is to correctly and objectively identify and control the level of risk to the patient. Maintaining the 10-ppm limit as a default to prevent excessive carryover is equally unjustified, as “visually clean,” a third criterion not discussed herein and which is almost universally implemented to satisfy the inspection criterion required by 21 

) 211.67(b) (15), is more than satisfactory to keep any product carryover low.

	The pharmaceutical industry has been moving toward a science and risk-based approach since 2001 with the roll out of FDA’s CGMPs for the 21st Century (16), the process analytical technology (PAT) initiative (17), the process validation guidance (18), and the ICH Q series guidelines, among others. While this movement has been slow, the authors believe that the time is right for cleaning validation to embrace a science and risk-based approach to acceptance limits, in conjunction with the process capability methods identified here.

	According to ICH Q9, “The level of effort, formality, and documentation of the quality risk management process should be commensurate with the level of risk.” Consequently, cleaning validation efforts should be focused on where the risks are, with the science behind the ADE informing us which products have the greatest risk (see 

). This was one of the stated goals of the Risk-MaPP Guide. The Cpu then informs us what the probability of patient exposure is and can be used to complete the calculation shown in 

	Continuing the use of 10-ppm and 0.001 low-clinical dose criteria obscures the true patient risk and presents a potential compliance gap as well as operational difficulties, which is why both of them should be abandoned. With the requirement to have established API-specific ADEs, the 10-ppm and 0.001 low-clinical dose should now be relegated to a chapter of history. The ADE must now be used for risk assessment for all products. In concert, statistical process control (SPC) methodologies should be used for establishing ongoing cleaning validation limits based on actual process data as has previously been described (12).

	The authors wish to thank Osamu Shirokizawa, Mariann Neverovitch, and Joel Young for reviewing this article and for their insightful comments and helpful suggestions.

, 40 (1) pp. 52-56 (January 2016).
	2. A. Walsh, 

, 31 (4): 74-83, (July/August 2011).
	3. G. Fourman and M. Mullen, 

 17 (4): 54-60, (April 1993).
	4. D. LeBlanc, “Residue Limits for Cleaning Validation in Finished Dosage Form Manufacturers,” PDA Letter, Parenteral Drug Association 2006 Survey on Cleaning Acceptance Limits, May 2007.
	5. Parenteral Drug Association, “Points to Consider for Cleaning Validation,” 

, Bethesda, MD, 1998.
	6. ECA Academy, “Justification of Limits for Cleaning Validation in the Manufacture of Active Pharmaceutical Ingredients,” May 14 2007, www.gmp-compliance.org/eca_news_928.html
	7. ISPE, 

ISPE Baseline Guide: Risk-Based Manufacture of Pharmaceutical Products (Risk-MaPP)

, First Edition (ISPE, September 2010).
	8. EMA, 

EMA Guideline on Setting Health Based Exposure Limits for Use in Risk Identification in the Manufacture of Different Medicinal Products in Shared Facilities

, EMA/CHMP/CVMP/ SWP/169430/2012, 20 November 2014, www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/11/WC500177735.pdf.
	9. D. LeBlanc, Risk-MaPP-Gate Website, https://sites.google.com/site/riskmappgate/home
	10. ICH, 

, Step 4 (ICH Nov. 9 2005), www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf.
	11. A. Walsh, 

 31 (5) 44-49 (September/October 2011).
	13. D. C. Montgomery, 

Introduction to Statistical Quality Control

,  7th Edition (John Wiley & Sons, Inc., Hoboken, NJ, 2013).
	14. Minitab Inc.  Minitab 17. State College, PA. (2016).
	15. 21 

) 211.67(b)
	16. FDA, Pharmaceutical cGMPs for the 21st Century Industry-A Risk-Based Approach: Final Report (FDA, September 2004 (FDA), www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/Manufacturing/QuestionsandAnswersonCurrentGoodManufacturingPracticescGMPforDrugs/UCM176374.pdf.
	17. FDA, 

Guidance for Industry: PAT-A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance 

(FDA, September 2004), www.fda.gov/downloads/Drugs/.../Guidances/ucm070305.pdf.
	18. FDA, 

Guidance for Industry: Process Validation: General Principles and Practices

 (FDA, January 2011), www.fda.gov/downloads/Drugs/.../Guidances/UCM070336.pdf.

	When referring to this article, please cite it as A. Walsh et al., "Cleaning Limits-Why the 10-ppm and 0.001-Dose Criteria Should be Abandoned, Part II," 

Conventional limit-setting techniques are not health-based and can make risk assessment more difficult.

Cleaning Limits—Why the 10-ppm and 0.001-Dose  Criteria Should be Abandoned, Part II

	The revised Chapter 5 of Part 1 of the European Union’s GMP guidelines and the European Medicines Agency’s (EMA) 

Guideline on Setting Health Based Exposure Limits for Use in Risk Identification in the Manufacture of Different Medicinal Products in Shared Facilities

 came into effect in 2015 (1, 2). Both publications expect the industry to use a “quality risk management process, which includes a potency and toxicological evaluation” when deciding whether to use dedicated or shared facilities to produce pharmaceuticals. Consequently, the same comprehensive approach based on health risks should be followed to determine the acceptable limits set for cleaning shared equipment. The authors believe it is the right time to abandon the 10-ppm rule in favor of more scientific and data-driven health based limits.


	Health authorities do not require shared equipment to be cleaned to 10 ppm of the next product. Careful reading of GMP regulatory texts (3-11), FDA’s 

Guide on Inspections--Cleaning Validation 

(12), and the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme’s (PIC/S) Recommendations on Cleaning Validation (13) yields no indication that any of these health authorities or PIC/S ever explicitly prescribed numerical cleaning limits. When it comes to cleaning limits, these guidelines all follow a similar discourse--they expect companies to abide by a general duty of care, sometimes adding that the limits should be “based on the knowledge of the materials involved.” Some of the texts mention the three traditional rules originally proposed by Fourman and Mullen (14) (i.e., visually clean equipment, residue levels ≤ 1/1000th daily dose, and ≤10 ppm of next product) as examples but never as binding rules. In this case, consistent with other performance-based regulations, the responsibility to establish and justify cleaning limits for shared facilities remains with pharmaceutical manufacturers.

	The 10-ppm limit goes against the basic principle of toxicology that it is the dose that makes the poison. Parts per million (ppm) is a concentration unit (i.e., a relative number and not an absolute one). In chemistry parlance, it is an intensive property (such as density or melting point) that is independent of the amount of the material, and as such, it is not suitable to describe a dose, which is an extensive property (such as mass or volume) that is dependent on the amount of material. Defined as a concentration, the limit dose will depend on the maximum amount of something else, in this case, on the amount of the following product (or API, the approaches vary) administered to the patient. Assuming that therapeutic doses range from 0.1 mg to 5000 mg per day, the amount of a contaminating substance corresponding to 10 ppm will span the same range of 4 logs. Using a limit of 10 ppm without risk characterization of exposure is equivalent to pretending that it makes no difference if a drug is contaminated by 1 ng (the equivalent of 10 ppm of 0.1 mg) or by 50 mcg (the equivalent of 10 ppm of 5000 mg) of the same substance.

	Whether the contaminant is Botox or a mild antacid, the limit amount computed by 10 ppm will be the same. Therefore, involvement of a risk assessment scientist (e.g., toxicologist or physician) is crucial for the characterization and differentiation of health risks and the overall risk management process. 

 compares the weight of scientific justification for three different approaches to compute the maximum safe surface residue (MSSR). In contrast to approaches targeting 10 ppm and 1/1000th of the daily dose, the permitted daily exposure (PDE) approach ensures that available preclinical and clinical data are considered in computation of the MSSR.

Does the 10-ppm limit ensure good cleaning?


	No; 10 ppm is a concentration unit that gives no indication on cleanliness. Operationally, a sensible physical unit for cleanliness must express the amount of residue per unit surface area (e.g., mg/m

). By switching from carryover (amount of residue [g]) to cleanliness [mg/m

], the surface is normalized, and the cleanliness of all pieces of equipment of a facility can be compared; cleaning results between facilities and even between companies can also be compared. When speaking of cleanliness, the size of the equipment does not matter; “cleanliness” is an intensive property of the equipment. Therefore, until the 10 ppm has been converted into a cleanliness value in [mg/m

], it is not possible to say what level of cleanliness the 10 ppm eventually represent. Depending on the particular situation, 10 ppm may mean 1 mg/m

Can 10 ppm be used to identify risks according to the EMA guideline on shared facilities?


	The EMA guideline (2) describes primarily a method for computing health-based limits based on all available toxicological and pharmacological information, which are termed permitted daily exposure (PDE). The 

guideline’s focus is not on how to set cleaning limits. The PDEs are only one element needed to set cleaning limits, which are calculated as MSSR. The other element is the knowledge of the efficiency of a cleaning process, which is independent from the next product. Therefore, while there is a link between PDEs and cleaning limits, they are absolutely not the same. This is expressed in the EMA guideline, which says, “these levels can be used as a risk identification tool and can also be used to justify carryover limits used in cleaning validation.”

	An evaluation of the effect of using 10 ppm in addition to PDE to identify risks was performed with the example of an actual product portfolio of a multiproduct API manufacturing facility making 11 different APIs. The basic data of the APIs are given in 

	All changeovers from a preceding product (α) to a following product (β) were considered. The matrix of maximum safe carryovers (MSC) was first calculated according to 

. In a second step, the matrix of MSSR was calculated by dividing the MSC by the equipment surface area used to make each following API (see 

	Each cell of the MSSR matrix shown in Table II reflects an individual product change from an API α to an API β and contains the MSSR for the particular change (i.e., the cleanliness required to make the corresponding API β when it is made after API α).

 shows a vivid landscape with strong contrasts, with values from 5 to 146,970 mg/m

. It is easy to identify the changeovers that pose the greatest risks. Comparing the calculated MSSRs with 

the results of approximately 250 swab results that were gathered over two years, 99% of all swabs gave results <25 mg/m

; high-risk changeovers are identified as the ones that require a MSSR of < 25 mg/m

	For example, the changeover from product D to product E was calculated as follows:
	

	Five products C, G, I, J, and K are potentially at risk, but only when they follow certain products, like A, G, I, and K. Similarly A, G, I, and K represent a risk for the other products, but not for all of them.

	The comparison of the matrix of MSSR based on PDE with the known efficiency of the cleaning processes allows for a sound identification of risks in line with the spirit of the EMA guideline. The comparison may give the concept of “worst-case approach to cleaning validation” a new orientation by shifting the focus from the hazards of worst-case products (with regard to solubility, cleanability, toxicity, etc.) to the worst-case risks, (i.e., to the “risky” changeovers between two products). Such risks will have to be mitigated, for example, by development of better cleaning procedures, avoiding high-risk changeovers by careful campaign scheduling and dedication of certain process lines or parts of the equipment to a group of products. It is important, however, to accept that cleaning will have its limits: There will be cases where the risk cannot be mitigated by cleaning alone.

	How does the risk identification work with the 10-ppm rule? Because the calculation is independent of the preceding products, the matrix collapses to a list of batch sizes divided by 105 (see 

based MSSRs all come out in a narrow range, between 9 and 59 mg/m2 and they do not really allow clear differentiation between the high- and low-risk changeovers. Compared to PDE, the 10-ppm calculation does not improve the detection of high risks.

	In practice, the 10-ppm methodology gives the impression that there are no low-risk changeovers. If the 10-ppm row in Table III is followed, whenever C, D, I, or K is made, the manufacturer has to meet the MSSR dictated by 10 ppm. The assumed cleaning limit of 25 mg/m

 will not meet the requirement to make C, D, I, or K in any case, independently of what the preceding product was.

 merely reflect the low risk associated with the corresponding changeovers. They should not be read as cleaning limits. The suspicion that production will set the cleaning limit at the level of the PDE-derived MSSR is not justified. Even if the MSSR values for particular changeovers are high, this does not justify reducing the cleaning effort, because cleaning will still have to fulfill the requirement of visually clean equipment. This will be sufficient to ensure a suitable minimal hygiene standard.

	The cleaning limit should also be based on the knowledge of the capability and the reliability of the cleaning processes, and it will ideally be set as far below the MSSR as reasonably possible.


	There is no scientific justification for a limit concentration that ignores the hazards presented by potential contaminants. Implementation of the 10-ppm criterion in cleaning validation does not ensure safe cleaning. and it may distort the identification and analysis of cross contamination risks. Moreover, it may impose more stringent limits for cleanliness than are required by health authorities without adding to the patient safety. Eliminating an unnecessary requirement serves to focus attention and resources on high-risk situations. The 10-ppm criterion offers no scientific or practical benefit and can be discontinued in cleaning validation practice.


	The authors would like to thank Ed Sargent and Courtney M. Callis for their views during compilation of this manuscript.


	1. European Commission, The Rules Governing Medicinal Products in the European Union; Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use (Brussels, August 2014).
	2. EMA, Guideline on Setting Health Based Exposure Limits for Use in Risk Identification in the Manufacture of Different Medicinal Products in Shared Facilities (London, November 2014).
	3. European Commission, Volume 4 Good Manufacturing Practice (GMP) Guidelines, Parts I & II, http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm, accessed Dec. 1, 2015.
	4. European Commission, Volume 4: EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 15: Qualification and Validation (Brussels, February 2014).
	5. FDA, Code of Federal Regulations, Part 211 Current Good Manufacturing Practice for Finished Pharmaceuticals, www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=211, accessed Dec. 1, 2015.
	6. Ministério Da Saúde Agência Nacional De Vigilância Sanitária, Dispõe sobre as Boas Práticas de Fabricação de Insumos Farmacêuticos Ativos (Brazil, December 2014).
	7. Agência Nacional de Vigilância Sanitária--Anvisa, Validação de limpeza para farmoquímicas, http://portal.anvisa.gov.br/wps/wcm/connect/2443e9804f1af51ea138bdc88f4b6a31/Guia+de+valida%C3%A7%C3%A3o+de+limpeza+para+Farmoqu%C3%ADmicas.pdf?MOD=AJPERES, accessed Dec. 1, 2015.
	8. Health Canada, Cleaning Validation Guidelines, Guide-0028 (Ontario, January 2008).
	9. South Korea, Good Manufacturing Practice for Medicinal Products for Human Use, Enforcement Regulation of Pharmaceutical Affairs Act [Annex 2], http://wenku.baidu.com/view/42de6028ed630b1c59eeb53e.html, accessed Dec. 1, 2015.
	10. South Korea, Provisions for Conducting Validation for Drugs, etc, The KFDA Notification No. 2009-173 (December 2009)
	11. China FDA, Good Manufacturing Practice for Drugs (2010 Revision), http://eng.sfda.gov.cn/WS03/CL0768/65113.html, accessed Dec. 1, 2015.
	12. FDA, Validation of Cleaning Processes (7/93), Guide to Inspections: Inspections of Cleaning Processes (7/93), www.fda.gov/ICECI/Inspections/InspectionGuides/ucm074922.htm, accessed Dec. 1, 2015.
	13. PIC/S, Recommendations on Validation Master Plan, Installation and Operational Qualification, Non-Sterile Process Validation, Cleaning Validation; PI 006-03 (September 2007).
	14. G.L. Fourman and M.V. Mullen, Pharmaceutical Technology, April issue, 54-60 (1993).

:
	When referring to this article, please cite it as M. Crevosier, "Cleaning Limits-Why the 10-ppm Criterion should be Abandoned," 

The 10-ppm criterion for the acceptable concentration of potential API in cleaning validation to minimize cross contamination into next product has been employed for many years. This article describes why the 10-ppm criterion, which was established based on analytical limitations and estimates of acceptability, is no longer necessary and why a risk-based approach should be universally adopted.